Promising Emerging Classes of Therapies in Non-Small Cell Lung Cancer

David Gandara, MD, Corey J. Langer, MD, Anne S. Tsao, MD, Alan B. Sandler, MD, and Mark A. Socinski, MD, each provide their opinion on the most promising emerging class of therapeutics in non-small cell lung cancer (NSCLC).

More from this Peer Exchange discussion: http://www.onclive.com/peer-ex....change/nsclc-advance

• Catégorie